Bisc Therapeutics
Biotechnology Research • 
Cleveland, Ohio, United States • 1-10 Employees
Company overview
| Headquarters | Cleveland, Ohio, United States |
| Website | |
| NAICS | 541714 |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at Bisc Therapeutics
Elizabeth Berezovsky
CEO
About Bisc Therapeutics
Bisc Tx is developing a first-in-class small molecule Bax inhibitor to halt retinal degeneration in Geographic Atrophy (GA)—a leading cause of vision loss with no effective treatment. Geographic atrophy (GA) condemns five million people worldwide to progressive, irreversible blindness—watching their central vision disappear as reading, driving, and recognizing faces become impossible. Despite two FDA-approved treatments costing $25,000+ annually, patients continue losing vision because current therapies target inflammation after retinal cells have already died. We have identified a fundamentally different approach: preventing retinal cell death at its source by targeting Bax, the master switch that controls when stressed retinal cells live or die. Our breakthrough allows damaged retinal cells time to repair and recover, preserving vision instead of merely slowing its loss.
Bisc Therapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Bisc Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Bisc Therapeutics has never raised funding before.
Australia
Netherlands
Singapore
United Kingdom
GermanyFrequently asked questions
4.8
40,000 users
